![Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study – ScienceOpen Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study – ScienceOpen](https://www.scienceopen.com/document_file/10b0bdab-1bb9-4e0e-bf15-44de728950a2/PubMedCentral/large.png)
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study – ScienceOpen
Ioannis-Isidoros Varthalitis - Head of 1st Medical Oncology Dept - HENRY DUNANT Hospital Center | LinkedIn
![XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis – topic of research paper in Clinical medicine. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis – topic of research paper in Clinical medicine.](https://cyberleninka.org/viewer_images/359181/f/1.png)
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis – topic of research paper in Clinical medicine.
![PDF) Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of Nosocomial Infection in Hospitals in Cyprus and Greece | Achilleas Gikas - Academia.edu PDF) Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of Nosocomial Infection in Hospitals in Cyprus and Greece | Achilleas Gikas - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/41414486/mini_magick20190219-1675-11grang.png?1550593269)
PDF) Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of Nosocomial Infection in Hospitals in Cyprus and Greece | Achilleas Gikas - Academia.edu
Ioannis-Isidoros Varthalitis - Head of 1st Medical Oncology Dept - HENRY DUNANT Hospital Center | LinkedIn
![Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping | Request PDF Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping | Request PDF](https://i1.rgstatic.net/publication/325476752_Phase_II_study_of_panitumumab_combined_with_capecitabine_and_oxaliplatin_as_first-line_treatment_in_metastatic_colorectal_cancer_patients_clinical_results_including_extended_tumor_genotyping/links/5fc1d718a6fdcc6cc6771504/largepreview.png)
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping | Request PDF
![PDF) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A Hellenic Cooperative Oncology Group clinical translational study PDF) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A Hellenic Cooperative Oncology Group clinical translational study](https://www.researchgate.net/profile/Ioannis-Sainis/publication/236967140/figure/tbl3/AS:669685704056848@1536676922750/Assessment-of-circulating-angiogenesis-modulating-proteins-as-therapy-activity-predictors_Q320.jpg)
PDF) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A Hellenic Cooperative Oncology Group clinical translational study
![Cancers | Free Full-Text | Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There? Cancers | Free Full-Text | Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?](https://www.mdpi.com/cancers/cancers-12-01907/article_deploy/html/images/cancers-12-01907-g001.png)